KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Novavax (NVAX) over the last 15 years, with Q3 2025 value amounting to -$28.7 million.

  • Novavax's Other Non Operating Income fell 28034.17% to -$28.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year decrease of 8334.07%. This contributed to the annual value of $40.4 million for FY2024, which is 671.84% up from last year.
  • As of Q3 2025, Novavax's Other Non Operating Income stood at -$28.7 million, which was down 28034.17% from $11.9 million recorded in Q2 2025.
  • In the past 5 years, Novavax's Other Non Operating Income ranged from a high of $64.0 million in Q4 2022 and a low of -$34.8 million during Q3 2022
  • Its 5-year average for Other Non Operating Income is $4.0 million, with a median of $3.7 million in 2024.
  • Examining YoY changes over the last 5 years, Novavax's Other Non Operating Income showed a top increase of 1463986.18% in 2022 and a maximum decrease of 75630.78% in 2022.
  • Novavax's Other Non Operating Income (Quarter) stood at $434000.0 in 2021, then skyrocketed by 14639.86% to $64.0 million in 2022, then crashed by 82.83% to $11.0 million in 2023, then grew by 19.58% to $13.1 million in 2024, then tumbled by 318.61% to -$28.7 million in 2025.
  • Its last three reported values are -$28.7 million in Q3 2025, $11.9 million for Q2 2025, and $10.1 million during Q1 2025.